Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development
June 05 2019 - 1:30PM
Business Wire
Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman,
Ph.D., will join the company as Senior Vice President and Group
Head of Oncology Research & Development, leading all early
oncology research, from discovery to proof of concept clinical
studies. Dr. Settleman, a leader in molecularly targeted cancer
therapeutics, the epigenetics of cancer drug resistance, and
personalized cancer medicine, will report directly to Mikael
Dolsten, M.D., Ph.D., Chief Scientific Officer and President of
Worldwide Research, Development and Medical at Pfizer, and will be
based in La Jolla, California.
“Dr. Settleman brings to Pfizer a breadth of experience in
fundamental cancer biology, cancer genetics, and innovative
thinking related to the role of tumor heterogeneity in the
development of drug tolerance and resistance. I look forward to
seeing his expertise help Pfizer further accelerate potential
breakthroughs for people living with cancer,” said Dr. Dolsten.
“Dr. Settleman’s distinguished career in both academic research and
drug discovery will be critical to Pfizer’s continuous pursuit of
new therapeutic paradigms in cancer research.”
Dr. Settleman will join Pfizer effective July 1 from Calico Life
Sciences, where he was Distinguished Principal Investigator and
Head of Oncology Research. Prior to Calico, Dr. Settleman led
Discovery Oncology at Genentech. His distinguished career as an
academic scientist started when he was a postdoctoral fellow at the
Whitehead Institute for Biomedical Research at Massachusetts
Institute of Technology in Dr. Robert Weinberg’s laboratory, before
joining the Harvard School of Medicine faculty in 1992. During his
18 years as a member of the Harvard faculty, Dr. Settleman was
named the Laurel Schwartz Professor of Oncology, served as Director
of the Center for Molecular Therapeutics and Scientific Director of
the Massachusetts General Hospital Cancer Center, and led the
Cancer Cell Biology program of the Dana Farber Harvard Cancer
Center. He has authored more than 240 peer-reviewed publications.
Dr. Settleman received his B.A. in Neuroscience from the University
of Pennsylvania and a Ph.D. in Genetics from Yale University.
“I am privileged to be joining a world-class team of scientists
who have made many important contributions to the landscape of
cancer treatments for patients over several decades,” said Dr.
Settleman. “There has never been a more exciting time in cancer
research and I look forward to helping advance and grow a highly
promising pipeline that includes a variety of targeted therapies
and immunotherapies, with opportunities for rational combination
treatments.”
Robert T. Abraham, Ph.D., who has led the Oncology Research
& Development group at Pfizer since 2011, has decided to retire
at the end of 2019. During Dr. Abraham’s tenure, ten new Pfizer
oncology medicines were approved, benefitting hundreds of thousands
of patients around the world. Pfizer’s Oncology Research and
Development group is focused on advancing next-generation cancer
medicines through a diversified and comprehensive approach to
target the tumor and the tumor microenvironment. With three
distinct groups, Tumor Cell Biology, Cancer Immunology Discovery
and Targeted Therapeutics, the organization is comprised of more
than 400 dedicated scientists. Dr. Settleman will also become site
head of Pfizer’s La Jolla Research & Development hub where
nearly 800 employees work each day in support of Pfizer’s oncology
mission. As of April 30, 2019, Pfizer’s Oncology pipeline includes
44 programs from Phase 1 through Registration.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world’s best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world’s premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us. We routinely post information that may be
important to investors on our website at www.pfizer.com. In
addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube
and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice
The information contained in this release is as of June 5, 2019.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or
future events or developments.
This release contains forward-looking information about Pfizer’s
oncology pipeline, including its potential benefits, that involves
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. Risks and uncertainties include, among other things,
the uncertainties inherent in research and development, including
the ability to meet anticipated clinical endpoints, commencement
and/or completion dates for our clinical trials, regulatory
submission dates, regulatory approval dates and/or launch dates, as
well as the possibility of unfavorable new clinical data and
further analyses of existing clinical data; the risk that clinical
trial data are subject to differing interpretations and assessments
by regulatory authorities; whether regulatory authorities will be
satisfied with the design of and results from the clinical studies;
whether and when any applications may be filed in any jurisdiction
for any of Pfizer’s oncology product candidates; whether and when
any such applications may be approved by regulatory authorities,
which will depend on myriad factors, including making a
determination as to whether the product’s benefits outweigh its
known risks and determination of the product’s efficacy and, if
approved, whether any such gene therapy product candidate will be
commercially successful; decisions by regulatory authorities
impacting labeling, manufacturing processes, safety and/or other
matters that could affect the availability or commercial potential
of any such gene therapy product candidate; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2018 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190605005791/en/
Media:Jessica Smith212-733-6213jessica.m.smith@pfizer.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024